Results 11 to 20 of about 368,028 (305)
Targeting Tumor Vascular CD99 Inhibits Tumor Growth [PDF]
Frontiers in Immunology, 2019 CD99 (MIC2; single-chain type-1 glycoprotein) is a heavily O-glycosylated transmembrane protein (32 kDa) present on leukocytes and activated endothelium. Expression of CD99 on endothelium is important in lymphocyte diapedesis. CD99 is a diagnostic marker
Elisabeth J. M. Huijbers +9 more
doaj +5 more sources
Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. [PDF]
PLoS ONE, 2015 Developed and tested for many years, a variety of tumor hypoxia detection methods have been inconsistent in their ability to predict treatment outcomes or monitor treatment efficacy, limiting their present prognostic capability.
Nathan A Koonce +8 more
doaj +4 more sources
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation [PDF]
Tumor Biology, 2017 Current vascular targeting strategies pursue two main goals: anti-angiogenesis agents aim to halt sprouting and the formation of new blood vessels, while vascular disrupting agents along with coaguligands seek to compromise blood circulation in the ...
Khaled Seidi +2 more
doaj +3 more sources
Targeting Calcium Channels to Block Tumor Vascularization [PDF]
Recent Patents on Anti-Cancer Drug Discovery, 2012 Blood vessels and endothelial cells (ECs) are highly versatile in order to accomplish local tissutal needs in the physiological and pathological conditions. Tumor vasculature, in particular, exhibits special morphological and functional features, partly due to the peculiarity of tumor-derived ECs (TECs).
MUNARON, Luca Maria +4 more
openaire +3 more sources
Recent advances of nanotechnology-based tumor vessel-targeting strategies
Journal of Nanobiotechnology, 2021 Tumor vessels can provide oxygen and nutrition for solid tumor tissue, create abnormal tumor microenvironment (TME), and play a vital role in the development, immune escape, metastasis and drug resistance of tumor.
Dongjie Zhu +8 more
doaj +1 more source
Acta Pharmaceutica Sinica B, 2022 Vascular abnormality is a hallmark of most solid tumors and facilitates immune evasion. Targeting the abnormal metabolism of tumor endothelial cells (TECs) may provide an opportunity to improve the outcome of immunotherapy.
Yunlong Shan +13 more
doaj +1 more source
Pharmaceutics, 2022 Modification with polyethylene glycol (PEGylation) and the use of rigid phospholipids drastically improve the pharmacokinetics of chemotherapeutics and result in more manageable or reduced side-effects.
Mohamadreza Amin +5 more
doaj +1 more source
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited [PDF]
, 2012 The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2)
Dumont, Daniel J. +2 more
core +1 more source
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources
Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model [PDF]
Cancer Biology & Therapy, 2014 Tumor endothelial marker 1 (TEM1, endosialin) is a tumor vascular marker with significant diagnostic and therapeutic potential. However, in vivo small animal models to test affinity reagents specifically targeted to human (h)TEM1 are limited. We describe a new mouse tumor model where tumor vascular endothelial cells express hTEM1 protein.Immortalized ...
Chunsheng, Li +10 more
openaire +2 more sources